Pharmacodynamic effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells (cEPCs) and calcitonin gene related peptide in patients with essential hypertension.
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2015
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Essential hypertension
- Focus Pharmacodynamics
- 03 Dec 2015 New trial record